59 results
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:21pm
assets, valuation of deferred income taxes, unrealized tax positions and business combination accounting.
Cash and Cash Equivalents
The Company … , an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:15pm
assets, valuation of deferred income taxes, unrealized tax positions and business combination accounting.
Cash and Cash Equivalents
The Company … , an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets
10-Q
2024 Q1
EX-10.3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
to this Agreement will give rise to any adverse tax consequences to any person pursuant to Section 409A and this Agreement shall be interpreted, applied
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
, unrealized tax positions and business combination accounting.
Cash and Cash Equivalents
The Company considers all highly liquid investments … income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
of a 43.5% tax credit for clinical expenses incurred in Australia. The location of the proof-of-concept (“POC”) plan has not been determined at this time … , and we will determine the ultimate location based on availability of facilities and patient population, costs, tax credits and centers of excellence
424B3
9yw1u1x 1na00
16 Apr 24
Prospectus supplement
5:45pm
10-K
zm7qmfnvmw ef6v92
16 Apr 24
Annual report
4:48pm
10-K
EX-19.1
706leuq9vjvq
16 Apr 24
Annual report
4:48pm
10-K
EX-3.3
xwitw7f2581sxpimgx
16 Apr 24
Annual report
4:48pm
10-K
EX-97.1
hvgwzbxp pqh
16 Apr 24
Annual report
4:48pm
S-8
EX-4.5
nje5g43v v9nww
12 Apr 24
Registration of securities for employees
7:22pm
S-8
EX-4.6
6c5pvu1tu uor9
12 Apr 24
Registration of securities for employees
7:22pm
8-K
EX-99.1
mc7g0
9 Apr 24
Chromocell Issues Letter to Stockholders from Chief Executive Officer
8:30am
8-K
EX-1.1
9psw2pvr
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
8-K
EX-4.1
32gfybj8
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
424B4
ravrlza2h v1sdtxsn
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
hj2r6s3 lsy
20 Feb 24
Prospectus supplement with pricing info
5:28pm
FWP
efq w81xhbwh70njc
12 Feb 24
Free writing prospectus
8:09am